Abstract:Objective This study assessed the real-world application, effectiveness, and safety of olaparib and niraparib as maintenance therapies in patients with platinum-sensitive recurrent ovarian cancer (PSROC) in China and investigated clinical factors associated with prolonged benefits of poly ADP-ribose polymerase (PARP) inhibitors to help guide clinician treatment-decision making in daily practice. Methods This real-world single-center retrospective cohort study was conducted at the Shandong Cancer Hospital and Institute. Archival data of consecutive patients diagnosed with PSROC who achieved a complete response (CR) or partial response (PR) after the last platinum-based chemotherapy and treated with olaparib or niraparib as maintenance therapy from August 2018 to September 2021 were collected. Results Overall, 106 women were included in the cohort. Seventy-two (68%) patients were treated with olaparib, while 34 (32%) received niraparib; 99.1% of the patients were diagnosed with high-grade serous carcinoma, and 73.6% had FIGO stages III–IV. Approximately 71.7% of the patients had received PARP inhibitors after the second platinum-based line and 44.3% of the patients achieved a CR in their last platinum-based therapy. The median platinum-free interval (PFI) after the penultimate platinum-based therapy was 10 (95% CI: 10–13.6) months. The median PFS was 21 (95% CI: 13–24.5) months and the median CFI was 22 (95% CI: 16–26.5) months. Consistent with the univariate analysis, the multivariate analysis identified three independent factors associated with prolonged progression-free survival (PFS) and chemotherapy-free interval (CFI): breast cancer susceptibility gene (BRCA) mutant type (p = 0.005 and p = 0.003); PFI ≥12 months (p = 0.01 and p = 0.006); and CR to last platinum-based therapy (p = 0.016 and p = 0.019). It was found that there was no appreciable difference in any grade 3–4 hematological AE between patients who received olaparib and niraparib. Conclusion Maintenance treatment with olaparib and niraparib is effective and well tolerated for PSROC patients in real-world clinical practice. Three clinical factors were identified that predicted prolonged survival under maintenance therapy with PARP inhibitors: BRCA mutant type, PFI ≥12 months, and CR to last platinum-based therapy. These findings should be further confirmed with an appropriately powered analysis in studies with larger sample sizes.

Secondary cytoreductive surgery followed by olaparib tablets as maintenance therapy in patients with BRCA mutated recurrent ovarian cancer: A multi-center retrospective study

A Phase II Trial of Cytoreductive Surgery Combined with Niraparib Maintenance in Platinum-Sensitive, Secondary Recurrent Ovarian Cancer: SGOG SOC-3 Study

Olaparib Maintenance Monotherapy in Chinese Patients with Platinum‐sensitive Relapsed Ovarian Cancer: China Cohort from the Phase III SOLO2 Trial

Overall Survival (OS) in Patients with Platinum-Sensitive Relapsed Ovarian Cancer (PSROC) Treated with Olaparib Maintenance Monotherapy: Update from the L-MOCA Trial.

A Retrospective Analysis of Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy in Patients with Recurrent Ovarian Cancer

Olaparib Maintenance Therapy in Patients (pts) with a BRCA1 And/or BRCA2 Mutation (brcam) and Newly Diagnosed Advanced Ovarian Cancer (OC): SOLO1 China Cohort

Secondary Cytoreduction Surgery for Recurrent Epithelial Ovarian Cancer Patients after PARPi Maintenance: A Multicenter, Randomized, Controlled Clinical Trial.

A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)

Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer

Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy

Interim analysis from a phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer: APGOT-ov4/ OPEB-01.

Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer

What Predicts the Clinical Benefits of PARP Inhibitors in Platinum-Sensitive Recurrent Ovarian Cancer: A Real-World Single-Center Retrospective Cohort Study from China

542P Efficacy of PARPi Monotherapy and the Impact of Subsequent Platinum-Based Chemotherapy in BRCA1/2 Mutant Ovarian Cancer Patients with Secondary Platinum-Sensitive Relapse

Efficacy of niraparib maintenance therapy in Chinese women with platinum-sensitive recurrent ovarian cancer with and without secondary cytoreductive surgery: Results from the NORA trial.

Olaparib and niraparib as maintenance therapy in patients with newly diagnosed and platinum-sensitive recurrent ovarian cancer: A single-center study in China

L-MOCA: An open-label study of olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer.

A real-world study of treatment patterns following disease progression in epithelial ovarian cancer patients undergoing poly-ADP-ribose polymerase inhibitor maintenance therapy

Experience in the use of olaparib poly (ADP-ribose) polymerase inhibitors in maintenance therapy of BRCA-associated ovarian cancer

Olaparib maintenance therapy for platinum‐sensitive relapsed ovarian cancer at a single institution: A retrospective study

Efficacy of Poly (Adp-Ribose) Polymerase Inhibitors Monotherapy and the Impact to Subsequent Platinum-Based Chemotherapy in Breast Cancer Susceptibility Genes1/2-Mutated Ovarian Cancer Patients with Secondary Platinum-Sensitive Relapse.